false 0001716947 0001716947 2024-05-28 2024-05-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares















Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): May 28, 2024 (May 28, 2024)




Ensysce Biosciences, Inc.

(Exact name of registrant as specified in its charter)




Delaware   001-38306   82-2755287

(State or other jurisdiction of

incorporation or organization)



File Number)


(I.R.S. Employer

Identification Number)


7946 Ivanhoe Avenue, Suite 201

La Jolla, California

(Address of principal executive offices)   (Zip Code)


(858) 263-4196

Registrant’s telephone number, including area code



(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ENSC   The Nasdaq Stock Market LLC


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐






Item 8.01 Other Events.


On May 24, 2024, Ensysce Biosciences, Inc. (the “Company”) was formally notified by the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the equity requirement in Nasdaq Listing Rule 5550(b)(1). Although the Company’s securities may continue to be listed on Nasdaq, Nasdaq stated that the Company must remain in compliance with all of Nasdaq’s listing requirements. There can be no assurance that the Company will be able to maintain compliance with all of Nasdaq’s listing requirements in the future.


Item 9.01 Financial Statements and Exhibits.


Exhibit No.   Description
99.1   Press release dated May 28, 2024, titled “Ensysce Biosciences Regains Compliance with Nasdaq”
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: May 28, 2024


  Ensysce Biosciences, Inc.
  By: /s/ Lynn Kirkpatrick
  Name: Dr. Lynn Kirkpatrick
  Title: President and Chief Executive Officer